The second and third most highly cited articles were clinical trials that focused on the treatment of TAO through intramuscular gene transfer of vascular endothelial growth factors and the effects of iloprost on the treatment of limb ischemia in TAO. This evidence concerns the gene VEGFA and limb ischemia.